Image:MonoclonalAb.jpg
From Wikipedia, the free encyclopedia
No higher resolution available.
MonoclonalAb.jpg (427 × 285 pixels, file size: 27 KB, MIME type: image/jpeg)
Monoclonal antibodies for cancer. ADEPT, antibody directed enzyme prodrug therapy; ADCC, antibody dependent cell-mediated cytotoxicity; CDC, complement dependent cytotoxicity; MAb, monoclonal antibody; scFv, single-chain Fv fragment. Modified from Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-129;
 |
This work has been released into the public domain by the copyright holder. This applies worldwide. In case this is not legally possible: |
File history
Click on a date/time to view the file as it appeared at that time.
| Date/Time | Dimensions | User | Comment | |
|---|---|---|---|---|
| current | 14:23, 16 December 2004 | 427×285 (27 KB) | Ramujana (Talk | contribs) | (Monoclonal antibodies for cancer; Modified from Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-129; {{CopyrightedFreeUse}} ) |
- Search for duplicate files
- Edit this file using an external application
See the setup instructions for more information.
File links
The following pages on the English Wikipedia link to this file (pages on other projects are not listed):
- Monoclonal antibodies
- Basiliximab
- Gemtuzumab ozogamicin
- OKT3
- Efalizumab
- Palivizumab
- Monoclonal antibody therapy
- Panitumumab
- Apolizumab
- Bapineuzumab
- Ecromeximab
- Oregovomab
- Lemalesomab
- Sulesomab
- Denosumab
- Gavilimomab
- Afelimomab
- Faralimomab
- Catumaxomab
- Ertumaxomab
- Adecatumumab
- Anetumumab
- Altumomab
- Anatumomab mafenatox
- Arcitumomab
- Aselizumab
- Atorolimumab
- Bavituximab
- Bectumomab
- Bertilimumab
- Biciromab brallobarbital
- Bivatuzumab mertansine
- Cantuzumab mertansine
- Cedelizumab
- Clenoliximab
- Ipilimumab
- Lerdelimumab
- Metelimumab
- Zanolimumab
- Ziralimumab
- Dorlimomab aritox
- Telimomab aritox
- Zolimomab aritox
- Elsilimomab
- Inolimomab
- Odulimomab
- Vepalimomab
- Galiximab
- Gomiliximab
- Golimumab
- Maslimomab
- Keliximab
- Lumiliximab
- Teneliximab
- Vapaliximab
- Tremelimumab
- Erlizumab
- Fontolizumab
- Ocrelizumab
- Pascolizumab
- Pexelizumab
- Reslizumab
- Rovelizumab
- Ruplizumab
- Siplizumab
- Talizumab
- Tocilizumab
- Toralizumab
- Visilizumab
- Pemtumomab
- Mepolizumab
- Exbivirumab
- Libivirumab
- Regavirumab
- Sevirumab
- Tuvirumab
- Felvizumab
- Motavizumab
- Inotuzumab ozogamicin
- Lintuzumab
- Matuzumab
- Nimotuzumab
- Sibrotuzumab
- Sontuzumab
- Tacatuzumab tetraxetan
- Tadocizumab
- Tefibazumab
- Tucotuzumab celmoleukin
- Epratuzumab
- Atlizumab
- Nerelimomab
- Urtoxazumab
- Pagibaximab
- Duntumumab
- Iratumumab
- Lexatumumab
- Mapatumumab
- Ofatumumab
- Pritumumab
- Votumumab
View more links to this file.
